| Current Price | $2.01 | Mkt Cap | $129.1M |
|---|---|---|---|
| Open | $1.90 | P/E Ratio | -2.57 |
| Prev. Close | $2.01 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $1.88 - $2.04 | Volume | 179,183 |
| 52-Wk Range | $0.51 - $4.16 | Avg. Daily Vol. | 352,214 |
| Current Price | $2.01 | Mkt Cap | $129.1M |
|---|---|---|---|
| Open | $1.90 | P/E Ratio | -2.57 |
| Prev. Close | $2.01 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $1.88 - $2.04 | Volume | 179,183 |
| 52-Wk Range | $0.51 - $4.16 | Avg. Daily Vol. | 352,214 |
The best Bull and Bear pitches based on recency and number of recommendations.
Potential to reshape relapsing and recurring AML, improving outcomes and tolerability of existing chemotherapy regimens.
I have a fairly straightforward problem with GlycoMimetics, which is that I think that their lead candidate rivipansel is dead and the share price has not declined to take this into account. Pfizer not initiated a phase III trial of rivipansel… More
Read the most recent pitches from players about GLYC.
Recs
TMFEBCapital
(71.76)
Submitted: 12/18/2017 3:28:42 PM :
Start Price:
$16.37
NASDAQ:GLYC Score:
-146.99
Potential to reshape relapsing and recurring AML, improving outcomes and tolerability of existing chemotherapy regimens.
Recs
manirg
(< 20)
Submitted: 12/2/2014 8:41:39 AM :
Start Price:
$8.45
NASDAQ:GLYC Score:
-182.99
Undervalued
Recs
Andyman
(71.91)
Submitted: 4/2/2014 10:12:16 PM :
Start Price:
$16.64
NASDAQ:GLYC Score:
-213.70
Love the science, management, and original investors.
The two guys who originally designed the selectin inhibitors on which GLYC's drug candidates are based both still work for the company. The inhibitors will allow the company can develop and license a whole family of drugs based on the same technology that treat diseases in which inflammation plays a crucial role. That's a huge pool of potential disease targets, and a huge pool of potential revenue.
The CEO was very smart to select a first target (vaso-occlusive crisis of sickle cell disease) that permitted the company fast-track AND orphan drug status with the FDA. That means a much shorter time-to-market. They could have gone with a disease that afflicts a bigger patient population, but they were able to get proof of concept for this new class of molecule much more quickly (and far less expensively) this way.
Their partnership with Pfizer when they were still just a tiny startup speaks volumes about the potential for this company. I'm in with real money.
Find the members with the highest scoring picks in GLYC.
drugtrader (59.29) Score: +191.65
The Score Leader is the player with the highest score across all their picks in GLYC.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| WildShaman | 77.35 | 7/9/2018 |
|
5Y | $16.93 | -88.13% | +54.44% | +142.57 | 0 Comment | |
| giftofgod | < 20 | 8/13/2018 |
|
1Y | $14.46 | -86.10% | +50.67% | +136.77 | 0 Comment | |
| DyingClub | < 20 | 8/3/2020 |
|
5Y | $4.18 | -51.91% | +30.09% | +82.00 | 0 Comment | |
| NorteClub | 88.32 | 6/11/2020 |
|
5Y | $2.83 | -28.98% | +37.18% | +66.15 | 0 Comment | |
| JohnnyCaffeine | < 20 | 12/28/2021 |
|
5Y | $1.51 | +33.11% | -10.63% | +43.74 | 0 Comment | |
|
drugtrader | 59.29 | 6/14/2021 |
|
5Y | $2.68 | -24.94% | +0.88% | -25.82 | 0 Comment |
| jboudos | 57.94 | 2/10/2023 |
|
1Y | $3.26 | -38.34% | +5.23% | -43.58 | 0 Comment | |
| foggs1 | 61.66 | 3/10/2021 |
|
5Y | $3.05 | -34.10% | +9.60% | -43.70 | 0 Comment | |
| kfassini | < 20 | 2/26/2021 |
|
5Y | $3.36 | -40.18% | +12.11% | -52.29 | 0 Comment | |
| microgroov | 67.65 | 1/25/2021 |
|
1Y | $3.81 | -47.24% | +11.32% | -58.56 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
